应用
利用单个 B 细胞筛选在数周内找到全人源苗头化合物
HuTg 小鼠与我们的 DiversimAb 平台一样,能产生强效、高度特异性的候选治疗和试剂抗体。Both platforms are fully compatible with our Beacon-based single B-cell screening, enabling high-resolution, high-throughput hit identification and sequencing in a few weeks. Twist 的 HuTg 小鼠工作流程特别适合单个 B 细胞筛选,因为它们能产生高产、活跃的 B 细胞群,而其他人源化小鼠平台通常不具备这种能力。
杂交瘤兼容工作流程
Twist also provides an end-to-end, adaptable hybridoma workflow for HuTg and DiversimAb mice that includes hybridoma generation, high-throughput screening, and sequencing to uncover promising hits.
